CRESCENT BIOPHARMA, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
CRESCENT BIOPHARMA, INC. (CBIO) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $209.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-07-30
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $209.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $248.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $289.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $333.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $209.00K 10-Q · filed 2026-07-30 |
| 2026-03-31 | $248.00K 10-Q · filed 2026-04-29 |
| 2025-12-31 | $289.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $333.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $377.00K 10-Q · filed 2025-07-31 |
| 2024-12-31 | $557.00 10-K · filed 2025-02-13 |
| 2024-09-30 | $5.51K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $15.18K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $29.44K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $48.18K 10-K · filed 2024-03-27 |
| 2023-09-30 | $71.27K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $99.13K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $9.42K 10-Q · filed 2023-05-03 |
| 2022-12-31 | $22.29K 10-K · filed 2023-03-29 |
| 2022-09-30 | $40.43K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $63.73K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $92.01K 10-Q · filed 2022-04-28 |
| 2021-12-31 | $125.18K 10-K · filed 2022-03-03 |
| 2021-09-30 | $163.09K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $205.64K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $252.70K 10-Q · filed 2021-05-03 |
| 2020-12-31 | $304.10K 10-K · filed 2021-03-02 |
| 2020-09-30 | $359.75K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $419.55K 10-Q · filed 2020-07-31 |
| 2020-03-31 | $483.39K 10-Q · filed 2020-05-01 |
| 2019-12-31 | $551.12K 10-K · filed 2020-02-28 |
| 2019-09-30 | $622.64K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $697.88K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $776.71K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |